Photodynamic therapy for cholangiocarcinoma: Overview and new developments

Current Opinion in Gastroenterology

Volumn 25, Issue 5, 2009, Pages 472-476

  Ortner, Maria Anna ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Biliary tract neoplasms; Cholangiocarcinoma; Photodynamic therapy

Indexed keywords

AMINOLEVULINIC ACID; DELTA ALA; FOSLIP; HEMATOPORPHYRIN DERIVATIVE; INTERLEUKIN 6; PHOTOFRIN; PHOTOSAN; SERUM ALBUMIN; TEMOPORFIN; UNCLASSIFIED DRUG;

ALBUMIN BLOOD LEVEL; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; BILE DUCT; BILE DUCT CANCER; BILE DUCT CARCINOMA; BILE DUCT OBSTRUCTION; BILE LEAKAGE; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CHOLANGITIS; COMPARATIVE STUDY; EMPYEMA; ENDOPROSTHESIS; EVIDENCE BASED PRACTICE; GALLBLADDER DISEASE; HEMOBILIA; HUMAN; HYPOTENSION; IMAGING; IMMUNOMODULATION; LASER; LIVER ABSCESS; METAL IMPLANTATION; PHOTODYNAMIC THERAPY; PHOTOTOXICITY; RECURRENT CANCER; REVIEW; STENT; THERAPY EFFECT; TUMOR VOLUME; UNITED STATES;

APOPTOSIS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; HEMATOPORPHYRINS; HUMANS; INTERLEUKIN-6; MESOPORPHYRINS; NEOVASCULARIZATION, PATHOLOGIC; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; STENTS;

EID: 69749121856     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e32832e6e1f     Document Type: Review

References (35)

1. Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001; 234:507-519. (Pubitemid 32946713)
2. Witzigmann H, Berr F, Ringel U, et al. Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to R1/R2 resection. Ann Surg 2006; 244:230-239. (Pubitemid 44305537)
3. Farley DR, Weaver AL, Nagorney DM. 'Natural history' of unresected cholangiocarcinoma: patient outcome after noncurative intervention. Mayo Clin Proc 1995; 70:425-429.
4. Valek V, Kysela P, Kala Z, et al. Brachytherapy and percutaneous stenting in the treatment of cholangiocarcinoma: a prospective randomized study. Eur J Radiol 2007; 62:175-179. (Pubitemid 46578186)
5. Prat F, Chapat O, Ducot B, et al. Predictive factors for survival of patients with inoperable malignant distal biliary strictures: a practical management guideline. Gut 1998; 42:76-80. (Pubitemid 28228391)
6. Chang WH, Kortan P, Haber GB. Outcome in patients with bifurcation tumors who undergo unilateral versus bilateral hepatic duct drainage. Gastrointestinal Endosc 1998; 47:354-362. (Pubitemid 28237504)
7. Kaassis M, Boyer J, Dumas R, et al. Plastic or metals stents for malignant stricture of the common bile duct? Results of a randomized prospective study. Gastrointest Endosc 2002; 57:178-182. (Pubitemid 36236755)
8. Glimelius B, Hoffman K, Sjoden PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7:593-600. (Pubitemid 26285639)
9. Lee J, Kim TY, Lee MA, et al. Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. Cancer Chemother Pharmacol 2008; 61:47-52. (Pubitemid 47512625)
10. Kim ST, Park JO, Lee J, et al. A phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer 2006; 106:1339-1346. (Pubitemid 43363912)
11. Kim MJ, Oh DY, Less SH, et al. Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study. BMC Cancer 2008; 8:374-383.
12. Huang Z, Xu H, Meyers AD, et al. Photodynamic therapy for treatment of solid tumors potential and technical challenges. Technol Cancer Res Treat 2008; 7:309-320. This review summarizes the basis of photodynamic therapy and discusses the recent progress and technical challenges of photodynamic therapy of solid tumors.
13. Abels C. Targeting the vascular system of solid tumors by photodynamic therapy (PDT). Photochem Photobiol Sci 2004; 3:765-771. (Pubitemid 39302977)
14. Nowis D, Stoklosa T, Legat M, et al. The influence of photodynamic therapy on the immune response. Photodiagn Photodyn Ther 2005; 2:283-298. (Pubitemid 43061346)
15. Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and antitumor immunity. Nat Rev Cancer 2006; 6:535-545.
16. Cheon YK, Cho YD, Moon JH, et al. Diagnostic utility of interleukin-6 (IL-6) for primary bile duct cancer and changes in serum IL-6 levels following photodynamic therapy. Am J Gastroenterol 2007; 102:2164-2170.
17. Ortner MA, Liebetruth J, Schreiber S, et al. Photodynamic therapy of nonresectable cholangiocarcinoma. Gastroenterology 1998; 114:536-542.
18. Ortner MA. Photodynamic therapy of nonresectable cholangiocellular carcinoma. Gastrointest Endosc Clin N Am 2000; 10:481-486.
19. Berr MA, Wiedmann M, Tannapfel A, et al. Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival. Hepatology 2000; 31:291-298. (Pubitemid 30078590)
20. Rumalla A, Baron TH, Wang KK, et al. Endoscopic application of photodynamic therapy for cholangiocarcinoma. Gastrointest Endosc 2001; 53:500-504. (Pubitemid 33586760)
21. Ortner MA, Caca K, Berr F, et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 2003; 125:1355-1363. (Pubitemid 37409755)
22. Harewood GC, Baron TH, Rumalla A, et al. Pilot study to assess patient outcomes following endoscopic application of photodynamic therapy for advanced cholangiocarcinoma. J Gastroenterol Hepatol 2005; 20:415-420. (Pubitemid 40469343)
23. Shim CS, Cheon YK, Cha SW, et al. Prospective study of the effectiveness of percutaneous transhepatic photodynamic therapy for advanced bile duct cancer and the role of intraductal ultrasonography in response assessment. Endoscopy 2005; 37:425-433.
24. Dumoulin FL, Horst E, Sauerbruch T, et al. Phase II study of photodynamic therapy and metal stent as palliative treatment for nonresectable hilar cholangiocarcinoma. Gastrointest Endosc 2003; 57:860-867. (Pubitemid 47231345)
25. Zoepf T, Jakobs R, Joachim C, et al. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol 2005; 100:2426-2430. (Pubitemid 43919672)
26. Cheon YK, Cho YD, Baek SH, et al. Comparison of survival of advanced hilar cholangiocarcinoma after biliary drainage alone versus photodynamic therapy with external drainage. Korean J Gastroenterol 2004; 44:280-287.
27. Kahaleh M, Mishra R, Shami VM, et al. Unresectable cholangiocarcinoma: comparison of survival in biliary stenting alone vs stenting with photodynamic therapy. Clin Gastroenterol Hepatol 2008; 6:290-297. This retrospective trial was the first comparative study in the United States demonstrating the survival advantage of photodynamic therapy in nonresectable cholangiocarcinoma.
28. McCaughan JS Jr, Mertens BF, Cho C, et al. Photodynamic therapy to treat tumors of the extrahepatic biliary ducts. A case report. Arch Surg 1991; 126:111-113.
29. Nanashima A, Yamaguchi H, Shibasaki S, et al. Adjuvant photodynamic therapy for bile duct carcinoma after surgery: a preliminary study. J Gastroenterol 2004; 39:1095-1101. (Pubitemid 39618794)
30. Wiedmann M, Caca K, Berr F, et al. Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma. Cancer 2003; 97:2783-2790.
31. Zoepf T, Jakobs R, Rosenbaum A, et al. Photodynamic therapy with 5-aminolevulinic acid is not effective in bile duct cancer. Gastrointest Endosc 2001; 54:763-764. (Pubitemid 33668686)
32. Kiesslich T, Berland J, Plaetzer K, et al. Comparative characterization of the efficiency and cellular pharmacokinetics of Foscan- and Foslip-based photodynamic treatment in human biliary tract cancer cell lines. Photochem Photobiol Sci 2007; 6:619-627. (Pubitemid 46889468)
33. Peireira SP, Ayaru L, Rogowska A, et al. Photodynamic therapy of malignant biliary stricture using meso-tetrahydroxyphenylchlorin. Eur J Gastroenterol Hepatol 2007; 19:479-485. (Pubitemid 46725754)
34. Wang LW, Li LB, Li ZS, et al. Self-expandable metal stents and trans-stent light delivery: are metal stents and photodynamic therapy compatible? Lasers Surg Med 2008; 40:651-659. This ex-vivo study showed that light delivery is reduced due to the shadow effect induced by metal stents. Tissue scattering can partly mitigate this effect. Therefore, PDT is feasible in metal stents if light dose is adjusted to compensate the reduction of light transmittance caused by the stent during treatment.
35. Prasad GA, Wang KK, Baron TH, et al. Factors associated with increased survival after photodynamic therapy for cholangiocarcinoma. Clin Gastoenterol Hepatol 2007; 5:743-748.